Gilead Reports Q1 2026 Earnings: Strong HIV Sales Drive Growth
Gilead (GILD) reported total product sales of $6.9 billion for the first quarter of 2026, a 5% year-over-year increase driven by growth in its HIV, oncology, and liver disease products. Excluding Veklury, sales rose to $6.8 billion, up 8%, primarily due to strong performance from Biktarvy, Trodelvy, and Descovy.
Tickers: $GILD
Topics: Biktarvy HIV drugs oncology products sales growth Trodelvy Veklury